Crucell N.V. and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6 cell line in its UMN-03 project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus. Also, the two companies will provide UMN Pharma with various services including vector construction, clo...